HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $5.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Terns Pharma (NASDAQ:TERN) and maintained a $5.5 price target.
March 15, 2024 | 10:25 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Terns Pharma maintains a Neutral rating and a $5.5 price target from HC Wainwright & Co.
The reiteration of a Neutral rating and maintenance of a $5.5 price target by HC Wainwright & Co. suggests a stable outlook for Terns Pharma. This indicates no significant short-term price movement is expected, as the analyst's view remains unchanged.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100